PepsRadar
⌕ Search
Content updated · how dates work
The claim
“Epitalon restores melatonin and improves sleep.”
Verdict: Unproven
Small studies, nearly all from one research network, report that pineal peptides raised night-time melatonin in older people whose levels were low. Most of that human work used epithalamin, a cattle pineal extract, not synthetic epitalon. No published study has measured sleep in people given epitalon, and FDA's 2026 review found no evidence that it works for insomnia.
The melatonin evidence is thin, and there is no sleep evidence yet. The only placebo-controlled human study of synthetic epitalon (40 women, 20 days, a spray under the tongue) reported higher melatonin in urine but did not measure sleep. Most other human results come from epithalamin, a different product. A lab test of rat pineal glands found epitalon did not change melatonin release.
Video overview · 3:24
How epitalon differs from the pineal extract epithalamin, the cell studies behind the telomere claim, the mixed animal lifespan results, why no published study has measured telomeres or lifespan in people given it, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page →
Epithalamin is a mix of peptides extracted from cattle pineal glands. Epitalon is a single synthetic peptide of four amino acids (Ala-Glu-Asp-Gly) that researchers designed from the extract's amino acid makeup. Websites often treat the two as the same thing, and the compounding nominations FDA reviewed listed epithalamin as another name for epitalon.
FDA does not. In its July 2026 review of epitalon for compounding, the agency wrote that it considers epitalon and epithalamin to be different substances. That matters here, because most of the human melatonin results credited to epitalon online were measured with epithalamin.
Sources: fda.gov · PubMed 40141333
In a 2004 study of healthy older adults, a course of epithalamin raised night-time blood melatonin in people whose pineal function was low to begin with. In people whose function was normal, melatonin tended to fall. A companion 2004 report found epithalamin shifted the timing of the night-time melatonin peak toward the pattern seen in younger people.
A 2011 randomized study followed 79 older people with coronary heart disease for three years: 39 received courses of epithalamin on top of standard treatment, and 40 received standard treatment alone. The authors reported a normalized daily melatonin rhythm and lower death rates with epithalamin. A 2007 review from the same researchers covers both epithalamin and epitalon and says older people with low pineal function showed higher night melatonin. Its abstract gives no patient numbers for either product.
All of these papers come from one research network (Ukraine's Institute of Gerontology in Kyiv working with St. Petersburg's Institute of Bioregulation and Gerontology, where epitalon was developed). We did not find an independent replication.
Sources: PubMed 15452611 · PubMed 15455130 · PubMed 22451889 · PubMed 17969590
A 2020 study enrolled 75 healthy women aged 40-50, mostly night-shift workers. The 40 with low levels of a melatonin breakdown product in their urine (6-sulfatoxymelatonin) were split into two groups for 20 days: a salt-water spray under the tongue, or an epitalon spray. Levels did not change on placebo and rose 1.7-fold on epitalon. The authors also reported changes in body-clock genes in blood cells.
FDA's review summed up its limits: the paper does not say whether it was blinded, it was small and short, and it did not measure sleep. The authors said 83% of the epitalon group improved in "psycho-emotional and general physical condition" against 25% on placebo, but did not say how that was assessed. The spray was also given under the tongue, not by injection, which is how epitalon is usually sold and was the route proposed to FDA.
Sources: PubMed 33280326 · fda.gov
In old rhesus monkeys, short courses of epitalon or epithalamin raised night-time melatonin, while young monkeys showed no change. A 2005 monkey study also reported lower fasting glucose and insulin in old animals given epitalon.
A 2003 study from a lab in Paris tested epitalon directly on pineal glands taken from young and old rats. At every concentration used, it had no significant effect on melatonin release, either on its own or when the glands were stimulated to make more. The authors concluded that, at least in the lab dish, the peptide does not seem to control melatonin secretion.
Sources: PubMed 14743609 · PubMed 15664732 · PubMed 12809170
Melatonin helps time the body clock, and night-time levels tend to fall with age. But a 1998 study found that melatonin output was not related to sleep in older adults, and FDA cited that finding in its review. Insomnia treatments are judged on sleep itself: how long it takes to fall asleep, total sleep time and how often people wake up.
We found no published study, and no registered trial on ClinicalTrials.gov, that measured any of those outcomes in people given epitalon. Epitalon is also not mentioned in the American Academy of Sleep Medicine's insomnia treatment guideline.
Sources: PubMed 9551850 · fda.gov · clinicaltrials.gov
Insomnia was the use FDA reviewed when epitalon was nominated for compounding. The agency's July 2026 briefing found no published studies of epitalon for insomnia and none of it given by injection. It proposed not adding epitalon to the list of substances pharmacies may compound, citing poorly characterized material, no human safety data, a possible risk of immune reactions, and the availability of approved insomnia drugs.
FDA's Pharmacy Compounding Advisory Committee voted 7-4 to recommend adding it anyway, according to news reports. That vote is advisory. On October 30, 2026, HHS published an interim policy saying it will not act against licensed pharmacies and physicians that compound epitalon while FDA writes formal rules. Neither step is an FDA approval, and neither involved new evidence that epitalon improves sleep.
Sources: fda.gov · statnews.com · federalregister.gov
These are original summaries of published research, written with AI assistance from the cited studies. Each reference was matched to its PubMed record by title, year and journal; the summaries themselves have not been independently checked line by line against the full papers, so errors are possible (corrections). They are not medical advice and have not been reviewed by a clinician. All claim checks · Editorial standards
See something wrong on this page? Report a mistake · Corrections